Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Am J Obstet Gynecol MFM. 2019 Mar 27;1(1):10–18. doi: 10.1016/j.ajogmf.2019.03.006

Table 2:

Changes in Measures of Tobacco Exposure

Placebo/Nicotine # of Subjects Placebo Mean (SD) Nicotine Mean (SD) P-Value* P-Value**
Cigarettes Per Day (Survey)
 Baseline 67/70 8.04 (4.59) 8.66 (4.71)
 Visit 2 32/43 5.03 (4.69) 3.48 (3.29) 0.009 0.022
 Visit 5 37/35 3.51 (2.69) 2.37 (1.78) 0.038 0.042
 Visit 6 41/47 2.85 (3.50) 2.43 (2.22) 0.041 0.108
Cotinine (ng/mL)
 Baseline 59/65 108.45 (62.65) 117.59 (77.40)
 Visit 2 38/47 89.87 (62.35) 88.09 (54.66) 0.143 0.131
 Visit 5 30/27 99.19 (62.20) 103.64 (66.91) 0.435 0.492
 Visit 6 26/39 85.48 (58.84) 87.97 (56.36) 0.290 0.229
Exhaled CO (ppm)
 Baseline 66/70 10.80 (7.28) 11.39 (8.34)
 Visit 2 33/44 7.94 (6.77) 9.14 (7.01) 0.883 0.637
 Visit 5 37/36 8.43 (7.33) 7.25 (5.23) 0.961 0.959
 Visit 6 40/46 5.50 (5.42) 6.7 (7.4) 0.754 0.907
*

Analysis of change scores for participants with follow-up data (completer analyses) by two-sample t-test assuming unequal variances and no adjustment for potential confounders.

**

Analysis of change scores for participants with follow-up data (completer analyses) by linear regression with adjustment for site and motivation to quit smoking.